Journal of Drug Targeting最新文献_第5页

Preparation of cationic liposomes loaded with Sirtuin 6 plasmid for the treatment of arthritis in rats. 载sirtuin6质粒阳离子脂质体的制备及其对大鼠关节炎的治疗作用。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-22 DOI: 10.1080/1061186X.2025.2542858

Xiaolong Yu, Yanjia Lu, Ruixiao Song, Jian Lu, Jinhe Guo

{"title":"Preparation of cationic liposomes loaded with Sirtuin 6 plasmid for the treatment of arthritis in rats.","authors":"Xiaolong Yu, Yanjia Lu, Ruixiao Song, Jian Lu, Jinhe Guo","doi":"10.1080/1061186X.2025.2542858","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2542858","url":null,"abstract":"Arthritis, ormalizedn by chronic joint inflammation, is increasingly prevalent due to global ageing, placing significant pressure on healthcare systems. Recent studies have identified Sirtuin 6 (Sirt6) as a promising therapeutic target for alleviating arthritis symptoms. This study investigates the therapeutic potential of Sirt6-loaded cationic liposomes in a collagen-induced arthritis (CIA) rat model. Sirt6-loaded cationic liposomes were prepared and ormalizedn using transmission electron microscopy, particle size distribution, polydispersity index (PDI), zeta potential, encapsulation efficiency, in vitro release, and stability studies. The optimal Sirt6 plasmid-to-liposome ratio was established at 1:1000. Characterisation confirmed a spherical morphology, with a particle size of 177.65 ± 2.09 nm, a PDI of 0.216 ± 0.013, and zeta potential of 21.78 ± 1.76 Mv. The liposomes exhibited superior release profiles and storage stability, thus maintaining their integrity for up to 30 days and achieving 90.77 ± 3.35% release efficiency within 24 h. In vitro, the endocytosis of Sirt6-loaded liposomes significantly increased Sirt6 protein expression in chondrocytes (p < 0.01). In vivo, treatment reduced inflammation in liver and spleen tissues and lowered pro-inflammatory cytokines associated with CIA (p < 0.01). These findings support Sirt6-loaded liposomes as a potential novel therapeutic strategy for treatment of arthritis.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-12"},"PeriodicalIF":3.9,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing exosome-based drug delivery for the management of pregnancy-related disorders: a new frontier in obstetric therapeutics. 利用基于外泌体的药物输送管理妊娠相关疾病：产科治疗的新前沿。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-20 DOI: 10.1080/1061186X.2025.2546492

Feihua Jin, Yaying Zhan, Shaomin Xu, Li Pan, Bingqing Chu, Jinghua Yu, Yupeng Wang, Wenli Xu, Zhimin Lu

{"title":"Harnessing exosome-based drug delivery for the management of pregnancy-related disorders: a new frontier in obstetric therapeutics.","authors":"Feihua Jin, Yaying Zhan, Shaomin Xu, Li Pan, Bingqing Chu, Jinghua Yu, Yupeng Wang, Wenli Xu, Zhimin Lu","doi":"10.1080/1061186X.2025.2546492","DOIUrl":"10.1080/1061186X.2025.2546492","url":null,"abstract":"Obstetric complications, such as preeclampsia, preterm birth, and foetal growth restriction significantly impact maternal and neonatal health globally, contributing substantially to maternal and perinatal morbidity and mortality. These conditions often result in long-term health sequelae for affected offspring, including neurodevelopmental disorders, metabolic syndrome, and cardiovascular diseases. Despite advances in prenatal diagnostics and neonatal care, therapeutic options remain limited due to challenges imposed by the placental barrier, such as poor drug permeability, low bioavailability, and safety concerns. Exosomes, naturally occurring extracellular vesicles, offer promising solutions as targeted drug delivery systems due to their excellent biocompatibility, low immunogenicity, and ability to cross biological barriers. Specifically, exosomes are gaining recognition for their roles in maternal-foetal communication and immunological regulation, presenting potential both as biomarkers and therapeutic carriers in obstetric care. This review synthesises current knowledge of exosome properties, their physiological and pathological roles in pregnancy, and explores their potential as innovative therapeutic delivery platforms. Additionally, the review addresses existing challenges in exosome technology, including production scalability, standardisation, and safety, and outlines critical directions for future research and clinical translation.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-19"},"PeriodicalIF":3.9,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of a poloxamer-based thermally sensitive gel and an HPMC-based standard gel used to increase sildenafil citrate retention in the uterus. 以波洛莫为基础的热敏凝胶和以hpmc为基础的标准凝胶用于增加枸橼酸西地那非在子宫内潴留的比较。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-18 DOI: 10.1080/1061186X.2025.2546491

Jinmei Ren, Shuxia Wang, Zhaoli Wu, Chenghao Zhang, Qing Zhang, Xinran Cui, Jiaxin Liu, Jingling Tang

{"title":"Comparison of a poloxamer-based thermally sensitive gel and an HPMC-based standard gel used to increase sildenafil citrate retention in the uterus.","authors":"Jinmei Ren, Shuxia Wang, Zhaoli Wu, Chenghao Zhang, Qing Zhang, Xinran Cui, Jiaxin Liu, Jingling Tang","doi":"10.1080/1061186X.2025.2546491","DOIUrl":"10.1080/1061186X.2025.2546491","url":null,"abstract":"Objective: Sildenafil citrate (SC) could promote uterine lining development, leading to successful embryo implantation. Due to the low oral bioavailability of the first-pass elimination of SC, it is necessary to develop a gel for vaginal administration to improve the efficacy.Methods: A vaginal gel was prepared using the cold method to increase the retention of SC in the uterus, which allows for prolonged contact between SC and the vaginal mucosa. A poloxamer-based thermosensitive in situ gel containing SC (SC-Tsgel) and an HPMC-based standard gel containing SC (SC-Cogel) were prepared. The rheological properties, in vitro drug release, and in vivo retention in the uterus of SC-Tsgel and SC-Cogel were compared.Results: The gel formulations significantly prolonged the time it took for drugs to be released following a release study. SC-Tsgel and SC-Cogel administered vaginally increased the duration of drug administration compared to SC solutions injected through the tail vein. Nevertheless, compared with tail vein injection of SC solutions or vaginal administration of the SC-Cogel, the retention of SC in the uterus was increased significantly after vaginal administration of the SC-Tsgel.Conclusions: Novel formulations of SC prepared with poloxamer 407 show promise as vaginal medication preparations for the management of a thin endometrium.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-8"},"PeriodicalIF":3.9,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research progress of microneedle drug delivery system in the treatment of autoimmune diseases. 微针给药系统在自身免疫性疾病治疗中的研究进展。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-14 DOI: 10.1080/1061186X.2025.2546477

Tiantian Wu, Xiaowei Li, Wei Wei, Yujing Wu

{"title":"Research progress of microneedle drug delivery system in the treatment of autoimmune diseases.","authors":"Tiantian Wu, Xiaowei Li, Wei Wei, Yujing Wu","doi":"10.1080/1061186X.2025.2546477","DOIUrl":"10.1080/1061186X.2025.2546477","url":null,"abstract":"Autoimmune diseases represent a heterogeneous group of disorders characterised by immune system dysregulation, wherein aberrant responses to self-antigens result in cellular and tissue damage. According to statistics, there are over 80 different types of autoimmune diseases worldwide, among which psoriasis and rheumatoid arthritis (RA) are relatively common. Current therapeutic strategies emphasise long-term management to mitigate symptoms and retard disease progression. Conventional approaches, including systemic administration of oral medications, injectables, and biologics, are frequently limited by adverse effects that compromise patient adherence. In contrast, the use of microneedle (MN) technology as a minimally invasive transdermal delivery platform has emerged as a promising alternative, offering distinct advantages such as painless self-administration, enhanced patient compliance, localised delivery to disease-specific sites (e.g. skin lesions in psoriasis, inflamed joints in RA), and improved bioavailability of immunomodulatory agents while minimising systemic toxicity. This review systematically examines MN classification, immunomodulatory mechanisms, and therapeutic efficacy in autoimmune disease management, while also providing a critical assessment of MN biosafety and clinical translation challenges in autoimmune patients. Furthermore, it highlights recent advancements in MN technology for prevalent autoimmune disorders, with the goal of informing future innovation and accelerating clinical translation.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-17"},"PeriodicalIF":3.9,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calpeptin promotes osteogenesis through the Dlx3-RUNX2 pathway: in vitro and in vivo evidence for a dual-action osteoporosis therapy. Calpeptin通过Dlx3-RUNX2途径促进骨生成：体外和体内双作用骨质疏松症治疗的证据。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-12 DOI: 10.1080/1061186X.2025.2546484

Pengruofeng Liu, Zimo Zhang, Xinyi Lin, Yao Chen, Tongzheng Sun, Weiming Guo

{"title":"Calpeptin promotes osteogenesis through the Dlx3-RUNX2 pathway: in vitro and in vivo evidence for a dual-action osteoporosis therapy.","authors":"Pengruofeng Liu, Zimo Zhang, Xinyi Lin, Yao Chen, Tongzheng Sun, Weiming Guo","doi":"10.1080/1061186X.2025.2546484","DOIUrl":"10.1080/1061186X.2025.2546484","url":null,"abstract":"Osteoporosis is a common systemic skeletal disease characterised by altered bone metabolism, decreased bone mass, deteriorated microstructure, and an increased risk of fractures. Current treatments primarily focus on inhibiting bone resorption to reduce bone loss. However, anti-resorptive agents alone cannot restore the lost bone microstructure. Therefore, developing dual-action drugs that both inhibit bone resorption and promote bone formation is a major research focus. In this study, we integrated network pharmacology and transcriptomics to screen for drugs that can be used to treat osteoporosis, and further identified compounds with potential synergistic effects in both inhibiting bone resorption and promoting osteogenesis. We found that calpeptin exhibited dual-intervention properties. Given its established anti-resorptive effect, we focused on exploring its osteogenesis-promoting mechanism. In vitro experiments demonstrated that calpeptin significantly enhanced osteogenic differentiation of BMSCs by activating the Dlx3-RUNX2 pathway. In an ovariectomy-induced osteoporotic mouse model, calpeptin treatment for 4 weeks alleviated bone loss and significantly promoted osteogenesis. This study reveals the unique mechanism by which calpeptin activates bone formation via the Dlx3-RUNX2 pathway, providing a new multi-target intervention paradigm for the development of breakthrough osteoporosis therapies.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-12"},"PeriodicalIF":3.9,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A dual-sensitive nanoparticle-mediated synergistic therapy strategy involving photodynamic therapy, chemotherapy and ICD stimuli to treat breast cancer. 双敏感纳米粒子介导的协同治疗策略，包括光动力治疗，化疗和ICD刺激治疗乳腺癌。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-11 DOI: 10.1080/1061186X.2025.2544806

Yuan Li, Haolong Qi, Yingjie Geng, Jianguo Gao, Xiaoqing Cai

{"title":"A dual-sensitive nanoparticle-mediated synergistic therapy strategy involving photodynamic therapy, chemotherapy and ICD stimuli to treat breast cancer.","authors":"Yuan Li, Haolong Qi, Yingjie Geng, Jianguo Gao, Xiaoqing Cai","doi":"10.1080/1061186X.2025.2544806","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2544806","url":null,"abstract":"The combination therapy strategy exerts a significant anti-tumour effect by synergistically eliminating tumour cells through the use of two or more treatments. Nanomedicine delivery systems are widely employed in cancer therapy owing to their ability to effectively improve drug solubility and enhance drug targeting. To this end, we have designed and developed a nano-targeted drug delivery platform PAE-PEG-ss-Ce6/DOX nanoparticles (PPCD NPs), for the co-delivery of the photosensitiser chlorin e6 (Ce6) and the chemotherapeutic agent doxorubicin (DOX). The nanoparticles exhibit a mean particle size of 128.74 ± 0.80 nm, demonstrating excellent serum stability and pH/glutathione (GSH)-responsive release characteristics in vitro. Compared to monotherapy, PPCD NPs exhibited enhanced cytotoxicity and cellular uptake, effectively inhibiting cell proliferation by inducing reactive oxygen species (ROS) production. The results of the immunogenic cell death (ICD) experiments demonstrated that PPCD NPs induced a robust ICD effect through the synergistic action of DOX and Ce6, thereby activating anti-tumour immunity and achieving combination therapy. In vivo experiments and histopathological analysis demonstrated that PPCD NPs exhibit excellent tumour targeting, high anti-tumour efficacy and low biotoxicity. These findings demonstrated the superiority of the phototherapy-chemotherapy-immunotherapy synergistic treatment strategy and indicate that PPCD NPs hold promise as a safe and effective anti-tumour nanoscale targeted drug delivery system.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-13"},"PeriodicalIF":3.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of valsartan-novasomes in the mitigation of atherosclerosis-associated diabetes mellitus: in vitro and in vivo assessment. 缬沙坦-新索体缓解动脉粥样硬化相关性糖尿病的有效性和安全性：体外和体内评估

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-08 DOI: 10.1080/1061186X.2025.2540849

Tamer Mohamed Mahmoud, Mohammed Ayad Alboreadi, Ala Hussain Haider, Amr Gamal Fouad, Amany Belal, Alaa Ismail, Mohamed A M Ali, Nisreen Khalid Aref Albezrah, Fatma I Abo El-Ela

{"title":"Efficacy and safety of valsartan-novasomes in the mitigation of atherosclerosis-associated diabetes mellitus: in vitro and in vivo assessment.","authors":"Tamer Mohamed Mahmoud, Mohammed Ayad Alboreadi, Ala Hussain Haider, Amr Gamal Fouad, Amany Belal, Alaa Ismail, Mohamed A M Ali, Nisreen Khalid Aref Albezrah, Fatma I Abo El-Ela","doi":"10.1080/1061186X.2025.2540849","DOIUrl":"https://doi.org/10.1080/1061186X.2025.2540849","url":null,"abstract":"Valsartan (VAL) offers protection against atherosclerosis-associated diabetes mellitus (AADM) due to its antioxidant properties. However, VAL is hindered by poor bioavailability and effectiveness, which can be attributed to its low water solubility and significant first-pass metabolism. This research aimed to develop a nasal VAL-novasomes formulation (VNF) intended to enhance VAL's efficacy, sustainability, bioavailability and targeting for AADM treatment. The Box-Behnken design was utilised for the development and optimisation of VNF formulations. The optimum VNF was subsequently evaluated in vivo using an experimental rat model of AADM. Compared to free VAL, the optimum VNF improved sustainability and bioavailability by 66.02% and 3.32-fold, respectively. The VNF group demonstrated significant reductions of 70.58%, 74.15%, 77.74% and 83.87% in glucose, triglycerides, cholesterol and LDL levels, respectively, compared to the AADM group. In contrast, HDL levels increased notably by 1.67-fold. Additionally, the VNF group accumulated 4.30 times more VAL in the heart than the free VAL group. Histopathological analysis confirmed the anti-atherosclerotic effect of the optimum VNF formulation. Importantly, the VNF group did not show any toxicity when compared to the negative control group. These findings support our hypothesis that the optimum VNF, administered nasally, could serve as a potential therapy for AADM.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-18"},"PeriodicalIF":3.9,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ofirnoflast: a first-in-class NEK7-targeted inhibitor of the NLRP3 inflammasome. Ofirnoflast: NLRP3炎性体的nek7靶向抑制剂。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-08 DOI: 10.1080/1061186X.2025.2542856

Alexis Mollard, Devan Bursey, William Burnett, Taylor Avei, Benjamin Bearss, Ramesh Subbiah, Viduth K Chaugule, Naga Srinivas Tripuraneni, Shipra Bijpuria, Russ Teichert, Chadwick Davis, Margit Janat-Amsbury, Jared Bearss, David Bearss

{"title":"Ofirnoflast: a first-in-class NEK7-targeted inhibitor of the NLRP3 inflammasome.","authors":"Alexis Mollard, Devan Bursey, William Burnett, Taylor Avei, Benjamin Bearss, Ramesh Subbiah, Viduth K Chaugule, Naga Srinivas Tripuraneni, Shipra Bijpuria, Russ Teichert, Chadwick Davis, Margit Janat-Amsbury, Jared Bearss, David Bearss","doi":"10.1080/1061186X.2025.2542856","DOIUrl":"10.1080/1061186X.2025.2542856","url":null,"abstract":"Ofirnoflast is a first-in-class, orally bioavailable NEK7 inhibitor currently undergoing Phase 2 clinical evaluation. It disrupts NLRP3 inflammasome assembly by targeting NEK7's scaffolding function-blocking complex formation independently of NLRP3 activation status, upstream of caspase activation, pyroptosis, and inflammatory cytokine release. This mechanism offers a novel therapeutic approach for chronic inflammation. Unlike NSAIDs, corticosteroids, cytokine-neutralising biologics, and NLRP3-directed small molecules-which are frequently limited by off-target effects, immunosuppression, or incomplete efficacy-ofirnoflast provides a targeted approach with fewer anticipated liabilities. We demonstrate that ofirnoflast engages an allosteric site adjacent to NEK7's ATP-binding pocket, inducing conformational shifts that impair its scaffolding function. In THP-1 macrophages and iPSC-derived microglia, ofirnoflast suppresses ASC specks, IL-1β release, and pyroptotic cell death. Biophysical assays and molecular dynamics simulations confirm that ofirnoflast stabilises NEK7 in a unique conformation and suggest a type-2 kinase-inhibitor binding mode. In vivo, ofirnoflast exhibits oral bioavailability, achieving systemic exposures well above cellular potency thresholds. In a DSS-induced colitis model, treatment significantly reduces cytokine levels and improves phsyiological outcomes. Collectively, these findings validate NEK7 as a druggable checkpoint for NLRP3 inflammasome control and position Ofirnoflast as a mechanistically distinct, clinically advanced candidate for treating inflammation driven by aberrant inflammasome activation.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-13"},"PeriodicalIF":3.9,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advancements in nanoparticle-based topical drug delivery systems for psoriasis treatment. 基于纳米颗粒的银屑病局部给药系统的最新进展。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-08 DOI: 10.1080/1061186X.2025.2544783

Ritwik Mitra, Dinesh Kumar Sharma, Arnab Ghosh, Sahil Senapati

{"title":"Recent advancements in nanoparticle-based topical drug delivery systems for psoriasis treatment.","authors":"Ritwik Mitra, Dinesh Kumar Sharma, Arnab Ghosh, Sahil Senapati","doi":"10.1080/1061186X.2025.2544783","DOIUrl":"10.1080/1061186X.2025.2544783","url":null,"abstract":"Chronic autoimmune skin disorder known as psoriasis (PSO) is typified by the excessive proliferation of skin cells, which develops thick, red and scaly patches on the skin's surface. These patches may be uncomfortable for people with this illness due to their itching and soreness. Treatments for psoriasis try to lessen inflammation, ease symptoms and slow the proliferation of too many skin cells. Traditional treatment methods for psoriasis, including topical corticosteroids, systemic immunosuppressant and biologics, often struggle with issues like poor patient adherence, systemic toxicity, limited skin penetration and inefficient drug absorption. However, nanotechnology-driven drug delivery systems offer a significant improvement by enhancing pharmacokinetic and pharmacodynamics properties. These systems ensure targeted and sustained drug release while minimising off-target effects, representing a promising new approach to PSO treatment. This article discusses various nano particulate drug carriers that have been developed to enhance transdermal and topical drug delivery. These carriers include liposomes, niosomes, transfersomes, ethosomes, dendrimers, nanoemulsions, solid lipid nanoparticles, nanogels, silver nanoparticles, gold nanoparticles, nanosponges, nanocapsules and nanocrystals. These nanocarriers improve the permeation of drugs across the stratum corneum, facilitate the formation of depots in the epidermis and dermis and enable controlled drug diffusion. This prolongs therapeutic action while reducing systemic exposure.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-18"},"PeriodicalIF":3.9,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protein biomarker modulation and wound healing efficacy of mentha piperita-based green-synthesized silver nanoparticles in alloxan-induced diabetic rats. 薄荷绿色合成纳米银在四氧嘧啶诱导的糖尿病大鼠伤口愈合中的蛋白生物标志物调控作用。

IF 3.9 4区医学

Journal of Drug Targeting Pub Date : 2025-08-07 DOI: 10.1080/1061186X.2025.2538223

Reema Aftab, Amber Afroz, Muhammad Irfan, Nadia Zeeshan, Awais Asif, Sabaz Ali Khan, Ahmed Mahmoud Ismail, Hossam S El-Beltagi, Bader Alsubaie, Othman Al-Dossary, Wael F Shehata, Hayfa Habes Almutairi

{"title":"Protein biomarker modulation and wound healing efficacy of mentha piperita-based green-synthesized silver nanoparticles in alloxan-induced diabetic rats.","authors":"Reema Aftab, Amber Afroz, Muhammad Irfan, Nadia Zeeshan, Awais Asif, Sabaz Ali Khan, Ahmed Mahmoud Ismail, Hossam S El-Beltagi, Bader Alsubaie, Othman Al-Dossary, Wael F Shehata, Hayfa Habes Almutairi","doi":"10.1080/1061186X.2025.2538223","DOIUrl":"10.1080/1061186X.2025.2538223","url":null,"abstract":"Background: Prognostic therapy for treating cutaneous wounds requires information about antioxidants and clotting factors in the tissue-remodeling phases.Purpose: To find the differential expression of potential biomarkers in diabetic rat wounds post-healing after confirming the stability of Mentha piperita-silver nanoparticles (MPAgNPs).Methods: MPAgNPs were characterized, and their bioactive compounds were identified by Liquid chromatography-tandem mass spectrometry (LC-MS/MS). Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is used to find differential protein expression in diabetic healed rat skin, followed by Quantitative Reverse transcriptase polymerase chain reaction (qRT-PCR) for their confirmation.Results: Scanning and transmission electron microscopy revealed spherical core metallic sizes of 50 nm. Dynamic light scattering determines the MPAgNPs' hydrodynamic size of 127 nm. The zeta potential value of -15.4 mV confirmed the NP's stability. Medioresinol, rosmarinic acid, caffeic acid, salvianolic acid, and methyl syringate were the bioactive compounds identified in M. piperita by LC-MS/MS. SDS-PAGE shows differential expression of anti-inflammatory, anti-apoptotic, antioxidant, and defense proteins. Antioxidant assays show increased levels of superoxide dismutase and glutathione peroxidase with decreased malondialdehyde. qRT-PCR confirmed enhanced expression of transforming growth factor, Thrombin, and Glutathione S-transferase P. At the same time, Tumor necrosis factor alpha, and Interleukin show reduced expression 16-D after MPAgNPs treatment.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1-14"},"PeriodicalIF":3.9,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0